Response of hairy cell leukemia to bendamustine
نویسندگان
چکیده
منابع مشابه
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
PURPOSE To determine tolerability and for the first time explore efficacy of bendamustine-rituximab (BR) in multiply relapsed/refractory hairy cell leukemia (HCL), using two different dose levels of bendamustine. EXPERIMENTAL DESIGN Patients with HCL with ≥2 prior therapies requiring treatment received rituximab 375 mg/m(2) days 1 and 15 plus bendamustine 70 (n = 6) or 90 (n = 6) mg/m(2), day...
متن کاملclinical and laboratory presentation of hairy cell leukemia (hcl) and rate of response to cladribine
introduction: hcl is a rare malignant condition that is curable if diagnosed early. hcl can present with reduced blood cells and splenomegaly which maybe misdiagnosed with other conditions. the aim of the present study was to determine the frequency of early clinical and laboratory findings as well as the response rate of patients to the standard treatment regimen of cladribine. methods: the st...
متن کاملCancer Therapy: Clinical Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
Purpose: To determine tolerability and for the first time explore efficacy of bendamustine–rituximab (BR) in multiply relapsed/refractory hairy cell leukemia (HCL), using two different dose levels of
متن کاملHairy cell leukemia-variant.
Hairy cell leukaemia variant is a very rare chronic lymphoproliferative disorder and is closely related to hairy cell leukemia. We hereby describe a case of hairy cell leukaemia variant for the first time in Saudi Arabia. An elderly Saudi man presented with pallor, massive splenomegaly, and moderate hepatomegaly. Hemoglobin was 7.7 g/dl, Platelets were 134 x109/l and white blood count was 140x1...
متن کاملDuration of response after interferon treatment of hairy cell leukemia.
Blood, Vol 75, No 12 (June 15). 1990: pp 2465-2468 times a week for an additional 18 months or until disease progression or intolerable toxicity. Response was evaluated on all 35 patients and was appropriately presented by prior treatment (none, splenectomy, and/or chemotherapy). The response rates achieved in this series appear similar to other reports. Durability of response was based on the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia & Lymphoma
سال: 2011
ISSN: 1042-8194,1029-2403
DOI: 10.3109/10428194.2011.562575